glp 1 hashimoto's disease Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study GLP-1 Medications and Autoimmune Thyroid
Description
Beyond obesity, the emergence of effective oral GLP-1s also highlights opportunities for a broader platform
Brands like Ozempic (for diabetes) and Wegovy (for weight loss) together contributed an estimated $25.4 billion in global revenues in 2024, highlighting the immense commercial potential
Brand-name GLP-1 medications face supply shortages, insurance denials, and authorization delays that leave patients waiting weeks or months to start therapy
Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1/CXCR7-AMPK/p38-MAPK/IL-6 axis
Nonetheless, any new or worsening symptom during treatment warrants clinical evaluation to determine appropriate management
Link: FDA Warning LetterRead the warning letters for a complete description of violations
